The effects of HIV protease inhibitors on carbohydrate and lipid metabolism
Authors:
- Grace A. LeeGLGrace A. Lee
- Madhu N. RaoMRMadhu N. Rao
- Carl GrunfeldCGCarl Grunfeld
- 1 March 2005
- journal article
- review article
- Published by Springer Nature in Current HIV/AIDS Reports
- Vol. 2 (1) , 39-50
Abstract
Since the introduction of HIV protease inhibitors (PIs), disorders of glucose and lipid metabolism have emerged. In dissecting out the direct effect on lipid and glucose metabolism, it has become apparent that individual PIs have different effects on metabolism. Some PIs such as indinavir acutely induce insulin resistance. PIs have also been shown to cause other disorders of glucose metabolism, including impairment of insulin secretion and increased endogenous glucose production. Individual PIs also have different effects on lipid metabolism. Ritonavir predominantly increases triglyceride and very low-density lipoprotein cholesterol levels. Limited studies in HIV-negative volunteers suggest that several of the PIs do not increase low-density lipoprotein cholesterol levels. This review examines the direct effects of PIs on glucose and lipid metabolism by assessing prospective studies of HIV-infected and healthy normal volunteers, and in vitro studies.Keywords
This publication has 75 references indexed in Scilit:
- Insulin secretion in lipodystrophic HIV-infected patients is associated with high levels of nonglucose secretagogues and insulin resistance of β-cellsAmerican Journal of Physiology-Endocrinology and Metabolism, 2004
- Risk of Metabolic Abnormalities in Patients Infected with HIV Receiving Antiretroviral Therapy that Contains Lopinavir‐RitonavirClinical Infectious Diseases, 2004
- Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjectsAIDS, 2003
- Increased VLDL-apoB and IDL-apoB production rates in nonlipodystrophic HIV-infected patients on a protease inhibitor-containing regimenJournal of Lipid Research, 2003
- Small dense LDL and atherogenic lipid profile in HIV-positive adultsAIDS, 2003
- Prospective, Intensive Study of Metabolic Changes Associated with 48 Weeks of Amprenavir‐Based Antiretroviral TherapyClinical Infectious Diseases, 2002
- Interactions Between Antiretroviral Drugs and Drugs Used for the Therapy of the Metabolic Complications Encountered During HIV InfectionClinical Pharmacokinetics, 2002
- The HIV protease inhibitor saquinavir impairs lipid metabolism and glucose transport in cultured adipocytesJournal of Endocrinology, 2002
- HIV Protease Inhibitor Induces Fatty Acid and Sterol Biosynthesis in Liver and Adipose Tissues Due to the Accumulation of Activated Sterol Regulatory Element-binding Proteins in the NucleusJournal of Biological Chemistry, 2001
- Plasma lipids in HIV‐infected patients: a prospective study in 95 patientsEuropean Journal of Clinical Investigation, 1994